Deutsche Bank cut shares of Hologic (NASDAQ:HOLX) from a buy rating to a hold rating in a research report sent to investors on Friday, MarketBeat.com reports. They currently have $49.00 price target on the medical equipment provider’s stock.

A number of other equities research analysts also recently weighed in on the company. Goldman Sachs Group upgraded Hologic from a buy rating to a conviction-buy rating and boosted their target price for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. Zacks Investment Research downgraded Hologic from a hold rating to a sell rating in a research report on Tuesday, October 17th. Cowen upgraded Hologic from a market perform rating to an outperform rating and set a $51.00 target price for the company in a research report on Monday, December 11th. Stifel Nicolaus restated a buy rating and set a $45.00 target price (down previously from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Needham & Company LLC restated a buy rating and set a $50.00 target price on shares of Hologic in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $48.79.

Hologic (NASDAQ:HOLX) traded down $0.39 during mid-day trading on Friday, hitting $43.46. The stock had a trading volume of 4,360,000 shares, compared to its average volume of 1,870,544. The company has a market capitalization of $12,088.73, a P/E ratio of 16.46, a P/E/G ratio of 2.09 and a beta of 0.95. Hologic has a 12 month low of $35.76 and a 12 month high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The company had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.52 earnings per share. analysts predict that Hologic will post 2.15 EPS for the current year.

In related news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Insiders sold 12,099 shares of company stock valued at $487,223 in the last quarter. 0.79% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hall Laurie J Trustee increased its holdings in Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after purchasing an additional 225 shares during the last quarter. Grove Bank & Trust increased its holdings in Hologic by 115.8% in the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares during the last quarter. National Asset Management Inc. bought a new stake in shares of Hologic in the second quarter worth about $203,000. MPS Loria Financial Planners LLC bought a new stake in shares of Hologic in the second quarter worth about $191,000. Finally, Rothschild Investment Corp IL bought a new stake in shares of Hologic in the third quarter worth about $236,000. Institutional investors and hedge funds own 97.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hologic (HOLX) Stock Rating Lowered by Deutsche Bank” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/01/20/hologic-holx-stock-rating-lowered-by-deutsche-bank.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.